研究中的β细胞衰竭和替代治疗方法
Domenico Accili1, Wen Du2, Takumi Kitamoto3,4
1Department of Medicine, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032 USA.
研究人员确定了阿尔代脱酶亚型1A3 (ALDH1A3) 作为2型糖尿病治疗的目标. 小分子FoxO1抑制剂通过将肠道细胞转化为产生胰岛素的细胞,对1型糖尿病具有前景.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 糖尿病研究 糖尿病研究
背景情况:
- 2型糖尿病涉及β细胞功能衰竭,与脱差相关.
- 贝塔细胞脱差的可逆性以前是不清楚的.
- 化脱酶亚型1A3 (ALDH1A3) 的激活是β细胞脱差的早期标志物.
研究的目的:
- 研究ALDH1A3在2型糖尿病中的作用.
- 探索2型糖尿病的新型治疗点.
- 使用细胞转化策略开发1型糖尿病的新疗法.
主要方法:
- 对β细胞脱分的分子基础的分析.
- 在动物模型中使用特定的ALDH1A3抑制剂.
- 在糖尿病动物模型中开发和测试FoxO1抑制剂.
主要成果:
- 在动物中,ALDH1A3抑制逆转了β细胞功能障碍.
- 口服FoxO1抑制剂降低了动物的血糖水平.
- 在NOD小鼠中产生产生胰岛素的耐自身免疫性肠道细胞.
结论:
- ALDH1A3是2型糖尿病的潜在药理目标.
- 福克斯O1抑制剂为1型糖尿病提供了一个新的治疗途径.
- 对于这两种方法,需要进行进一步的临床前研究.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
09:31Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
Published on: June 25, 2012
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Insulin Secretory Vesicles
